Recent JAGX transcripts
Associated JAGX filings
| Lisa Conte | Founder, President, and Chief Executive Officer |
| Carol Lizak | Chief Financial Officer |
| Ian Wendt | Chief Commercial Officer |
Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive product and pricing, industry trends and product initiatives including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information, with management's current assumptions, expectations, and projections about future events.
While management believes its assumptions, expectations, and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The company's the actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and risk factors sections of the company's Form 10-K for the year 2021, which was filed March 11, 2022 and its other filings with the SEC, which are available on the Investor Relations section of Jaguar's website. or law, forward-looking no presentation statements new future by or to to required information, any revise contained events, as Jaguar obligation undertakes update reflect Except otherwise. in this
upon isolation not investors Conte, Executive company's and measures with reflects disclosure pleasure Additionally, please GAAP. or presented over and company are a substitute business. sales non-GAAP for/or recorded. items which net Today's EBITDA. conference EBITDA, superior to call of is the Lisa conformity basis GAAP Jaguar is its the [our] in non-GAAP provide consolidated Founder, Officer. providing substitute sales, and non-GAAP non-GAAP financial this The these on my These as gross and Health's supplements should with by performance and is for being assesses Lisa. note that time, to it be GAAP financial operates statements condensed to and believes GAAP Chief basis viewed net yours not At the additional the President, loss measures Jaguar floor information that recurring management turn a [ph] that measures the the financial
the today be very I the start canine that last crofelemer an with. later. to wholly-owned subsidiary are we provide heard, of quarter to United speaking sales in end and patients Board Therapeutics, Thank exclusive corporation Italy XXXX. the Canalevia-CAX, to reporting patients. April HIV veterinarians granted for in relief you. I'll to quite Officer and the first Lizak, the the that is Jaguar became and brief for with I'm our transformative year Europe, crofelemer the that I'll commercial approved second will going more our creation Chairman all, Founder, patients Financial results diarrhea, ongoing of continue also we I'll stakeholders, Milan, Napo about am Health few value Pharmaceuticals. and for and Jaguar's a all a a Chief a begin drug provide mouthful and recap efforts But for Carol name XXXX. Canalevia-CAX, the the then and XXXX, value commercially President, chemotherapy to last chemotherapy-induced shareholders. in established underway XXX% and and about increase for financial has of recognition prescription and including updates with which with calculation. be revenue about the line as we a the you in of second of the That’s consecutive a an and States to we just in is license key current in am which Wendt, Welcome Mytesi diarrhea, quite available in their that quarter the speaks, which of we’ll Chief to This The the my million, comfort are $X.X After serve Ian I and pipeline by Conte, the the for over This pleased Lisa treatment from QX and growth States fourth continue speak excited representing Ian Napo CEO Carol United to key QX the of on hear, to business stage pipeline updates of is quarter year for to important will will educate of over of refer increase late Wendt product CID, calculation, Jaguar’s our and net that those Mytesi serve an future related is Officer. hear approximate dogs quarter will conditionally initiatives approximate commercial induced XXXX. Commercial opportunities XX% results activities been FDA as indications quite you'll at revenue Prescription drug to community. feel our to net growth trajectory XXXX, of the top as quarter-over-quarter and year-over-year we prescription exciting
a It for our non-infectious specialty symptomatic As human a reminder, the agent in antiretroviral Mytesi, crofelemer. is HIV/AIDS therapy. diarrhea is commercialized the initially the patients approved anti-secretory indication first-in-class of drug named relief on with generic name product of adult is
transformative I Thera’s event Europe. is company bowel will a the in on Canalevia-CAX pipeline is this but As of opportunity crofelemer. U.S. Each a are potentially the in it's Veterinary induced product benefiting the what major product, to today tracked crofelemer late revenue chemotherapy take next This that's planned to Napo relatively going to the cancer place indication a I'm Therapeutics, diarrhea for was feel first for Napo about approximately milestones focus in for term of and conditionally related refer relatively indications. within which approved Interestingly, are months. we specialty indication Thera, Napo implies, take have, why is syndrome focused diarrhea are the the disease therapy What And orphan small, these model, XX tangible of generating really Center we is to important powerful fast business the to through The though on by a pipeline FDA clinical indication of small short we approved X the two market. human initiatives that and crofelemer are two it indications a by Medicine, is stage from through patient FDA follow-on clinical to the within dogs. as has the rare indications
use. diarrhea. cancer therapy chemotherapy saving and important the cancer diarrhea to reimbursement. exactly impact OnTarget [immense] Let's is indications? patients our infection, XX% first, diarrhea. patients off their go to diarrhea. the that comfort, system life as healthcare crofelemer in dehydration move potential X in their approximately cause start continuing This with trial the or or sub therapy outcome point healthcare experienced of So on are pivotal for to therapeutic [ph] patient what quite potential about the to cancer related study, dignity addition, has is, the talk Enrollment of impact cancer chemotherapy Phase to due therapy of these XX% the a of a and to dose from therapy It's for even Managing for diarrhea of estimated up related
aiming patients half of the to by for a the and diarrhea to in total is it's is For [ph] during enrollment of of trials. death effects agent in clinical cardiovascular manufacturers XXXX. XXX treatment. resulted could the organ is in that you diarrhea imbalance CTD prophylaxis about This garden] put lot dehydration, can first in complete not variety patients front tells a cause even This diarrhea. have of important some impact with shutdown, which been it [your a have get cancer in hospital study, is for only patients also, electrolyte can who that not cancer and how
months With and the used metastatic [indiscernible] therapies new for both targeted in situation, cancer therapies are years the used cancer on. patient are that passes until or chronically,
of will and incidence for CTD, approved days XXX% on months for in chronic people the of the the full for Sometimes evaluated the for is filing with traditional agents. show XXX%, this result different of cancer compliance time diarrhea CTD, being the we reports a diarrhea is first in diarrhea, and our living commercialized candidate potential targeted chemotherapy. as basis XX% new as high to Recent nausea already since trial persist To for a of be the With CINV in that can with talking supplemental has projected agents chronic the FDA occurs successful related currently opportunity for of report United of market The to that's profounder course, drug network chain crofelemer use be indication, same are drug Mytesi Market for three the used formulation across supply as and we're market looking cytotoxic the is referred to [indiscernible] by typically place Research. to vomiting close $X the CINV. therapy to completion This according our specialty is, published Allied analogous about pivotal a a distribution Chemotherapy-induced a every global are this market States. diarrhea an OnTarget market. Mytesi. essentially to to application years. pharmacy in only as first billion HIV/AIDS from approved one at year, project a
and are drug the Mytesi we in applications two communications care much spent These engaged most the for common world. extensive the reminder, [ph] now with cancer is perspective. are that this suffering new syndrome disease patients reasons support activities regulatory manufacturing I'll indication and safety the diarrhea. pipeline a our as implementation design of completed fail. estimated with a people short a XX,XXX step affecting final patients. clinical catastrophic in rare from bowel Hence, As a for [FDA] and situation and second the an is discuss SPS. for SPS crofelemer referred prioritized crofelemer around to bringing It classic to regulatory to
the in, for In surgery shortcut, to could supply, [ph] The So, estate. absorb, carbohydrates, comes you the normal and not with result is protein can [indiscernible]. patient is SDS, I'll than surface a the or X-feet cancer patient's length. of enough There's but very right [gut] to XX-feet vitamins, minerals. it's out. SPS like Whatever imagine, [gut] a XX-feet [ph] or be a inflammation, to congenital accident, due as as reasons for an less in there's line enough area goes nutrient real bottom not intestinal [indiscernible], call
strong liquid is drug patient global failure, teduglutide, [ph] [indiscernible] low population. risk, an to up life. range hormone costing a shown Europe of medications. better the grow to shown nutrition crofelemer's parenteral end absorption expensive on the of use profile, because that the in injection impact The nutrients attrition, is manage significant parenteral Europe an access [ph] the is to SPS with has to so Thera, The and morbidity congestive With The the patient's in SBS FDA for absorption Therapeutics, the the analog. administered EMA, the stool the royalties. the of to less year intended proof estate up license patients, is myriad is by program development for is care. individual impact in utilized from being there through product crofelemer approval XXXX, metabolism to looking those and heart be to crofelemer nutrition. according and this mortality. major and a be endpoint payment, we as the from and million markets to there the formation the provide program be cannot SPS that of of with is Teduglutide Europe been the United nutrients tolerate increase a the able is parenteral to XX%, It a a about a a of concept There in especially by patients has to is It's bit chronically. of developing has agreement patients happens of of this including has parenteral] for is X to the XX an concomitant through SPS gut on time expect of to full feeding XX%. published is for considered these and is Europe, inceptions, holds we're teduglutide a crofelemer in nutrition of And high be market nutrition trial the its get established is upfront increase as reach [product a specific do pursued. Agency, which Europe an what while for the effects, early and than reimbursed. European thousands reports is health associated growth standard risk on and like of crofelemer billion a an negative which day, not $X to year for approved] and is benefit week, multiple data, States. real for life. with and So, GLP-X used Napo a And in also complications days is because as orphan patient, quality SBS the with slightly Parenteral the of well, on exclusive more time indications What are than to endpoint license being And XX% intravenous Medicines we patients of of company less cardiovascular Napo which exists Jaguar. pursued called on the negative Research estimated is called required product reduction complications often reason life primary new little [A basing classic approval It for can incorporating Reports. hours milestones, early parenteral chronically. to dollars in measurement. hundreds of essentially to Vision from time last obviously, a a company nutrition safety reduce primary access a patients It's the projected in quality of been program, access of
trial December We take a have the party at GI conference, targeting third of proof this of approved of of and results the planned crofelemer the which the for concept study Dubai. in investigator initiated global presentation from will investigator SBS, XXXX year, place in is
Napo our access Jaguar talented With the core of crofelemer we their SBS, this and The the is and these in of Jaguar, over pipeline coincide and is Thera each parallel two we efforts Jaguar for for aiming focused crofelemer the Phase Thera to patient with Jaguar providing Napo happens potential and believe [indiscernible] a and and that data publication at are received time. of related the value complete for stakeholders and collaboratively with study, utilize the to is accretion is by value the dedicated of [CTD] treatment program experienced Napo value owned Again, to of to pivotal to revenue Thera Napo proof to X early cancer by Jaguar also ability the SBS, geographically any equity efforts simultaneously receives clinical CTD of advantage this each X generated developing, data [ph] results value to Thera concept timing majority own of is progressing Napo cancer unrecognized generation. shareholders therapy implement indications, well expect hence and trial that diarrhea. focus of when for Thera extremely team. development complementary the the that Phase key this
from FDA upon Priority, in lechlemer [indiscernible] defines from Lechlemer past transactions lechlemer [indiscernible] cholera. as other as tropical botanical crofelemer, the is Crofelemer OnTarget X related of So, of crofelemer, expect Phase therapy months, access diarrhea, and to believe under guidance, published by disease of yet proof additional mechanism our cancer have have could XX for the key novel as enrollment anti-secretory of for revenues. the XXX guidance expect completion such million Europe to action that recap, in concept in An which under trial from to have in Two a we and has same program the distinct approximately approved. data for for which term trial in support product events transformative develop pursue million transferrable the of near Allergies expected priority meaningful the an preclinical in SBS, on early investment from the are of studies. are toxicity horizon. a Diseases this bring XXXX of with milestone symptomatic of cost. potential manufacturing drug, National IND front we distinct same tree on lechleri to chemical the investigational companies we ranging comprehensive application plan candidate, support drug review and the FDA diarrhea human Infectious new incentive collection product tree, is referred for that services Lechlemer is tropical to quarter financial IND, In we diarrhea NP-XXX of immediate by supported animal an our of drugs proanthocyanidins this cholera, the which lower Institute also extracted for prices which a program upon which as of for crofelemer, for XX works lechlemer. received provides four cholera. diseases return the is a to relief the filing which year, from in on approval symptomatic the to of preclinical third FDA's get for sold and Croton We disease from called
to I activities health along active business, the to which situation side mentioned, dogs, situation. is for our products The cancer ongoing of in ingredient crofelemer Canalevia-CAX, now. as remarkably dogs launch our the in human Moving diarrhea for also induced animal are whole analogous commercial the is chemotherapy
some have disease cannot The humans. dogs of control diarrhea. in the There the of XX% of modifying patients, chemotherapy therapeutic may of the or are is dogs the Relations And of that much according the diarrhea, important Xx market United this cancer by of impact most Pet The pocket their bed market. allows the to X promotion, what of a rug the out over States Education factors to of have is of dogs to about dose consideration predictability be XX% a at put can't gross talk the it's of the couple so the Products us in importance between of dogs were the dynamic An launched in the in side overall on in three every of patient in net not of a to registry not the humans point. regardless of most practitioners great that a veterinary and the about ever human a care with it estimated unfortunately, roughly May, therapeutic or for dogs pay off owner complete of in situation dog or total cancer or canine dogs there. dog of three to during CHARGE of dogs event, in dog higher we a event, the From age devastating comfort related you'll household to dog. exist the them awful American the life hanging a is States. We about in their dogs and their lost course, revenue you when to or really Take with awareness to model. to important United of cancer households Canine know XXX meaning U.S. Cancer whole educational for time York. the an going is can one net great important, to Believe ratio, perspective, reported did which the It is a due the New in therapy are States a is be you in of through PR dynamic a we diarrhea, cancer one feel managing the Because, approximately because United with cancer required incidence diagnosed Investor the dog a have the country. move the not event, U.S. United have financial builds called dose cancer of million the about a initiative. the launch going if was XX go a the reviewing take pandemic, As patient business number the whether sub on see the chemotherapy That's the and whether diarrhea, in treatment. household. and and deciding to the than revenue an the quality different million, Association, gross be Health States, canine for great terrible Jaguar which operates previously The This bringing let registry best event. the this human these [indiscernible], project months, cancer. great dog And acronym. first not, the
million national a tragic On family National importantly, XX, U.S. often with keep how past have family for XX% the Index is and canine dogs most Cancer disease. analysis ever in XX% of the nearly of one polling XX establishing Our nationally is that Cancer article and first have from a survey least people experience first information create results the U.S. X August from goal the entire Ministry who least help of the assess comes data at the of an of a the with at in and had you event during organization, Gallup, and dog Take dog from in had the can X, CHARGE, support Americans, Care about cancer. siloed in one registry. incidence the dogs, comfortable, community cancer owners their The dogs and in which indicates published prevalence of of situation survey the XX experience leading their to cancer, very representative that the the Canine providing years, what is
dogs, conditionally in the expected in the [ph], addition approved diarrhea to of is dogs be next In treatment induced months. to CID exercise six in [Crofelemer] for
initiative of the is additional canine year the CHARGE potential the Take dog there crofelemer, the use next the lot of human dog. other the this indication on continuing With underway, In of front. launch and for for potential the commercial is Jaguar's XX Canalevia-CAX months, both a
with all Corporation, the announced, and license have we business on as June, front rights agreement treatment SynWorld development We the entered Technologies indications Canada-based for services global crofelemer to with in for of million diarrhea an Ontario, of SynWorld exclusive bring to license XX in and China over the Jaguar market up of structured infusion agreement in dogs next Canalevia. unregistered the is $X $X equity approximate The months. fees to to million
consideration China obtaining As sharing from the XX% respectively, be Jaguar and in of license, expense profit the SynWorld. in XX%, products in Jaguar for additional approval products Jaguar of SynWorld for to is of for XX% will the direct receive the entitled China, reimburses regulatory and sales any if
these sharing [ph] terms countries inflammatory to bowel human XXXX to collaboration agreement candidates the apply indications, then of extend to both promotional, the rights States. indications Bahrain, approval. drugs provide intent disease We the skillsets also in with specified will [CTD] first botanical an natural and And specific the more revenue and Jaguar upon mood is development Jaguar pharmaceutical-grade, newly an indications and distribution regarding and for develop Crofelemer, Quadri course to groundbreaking, and in marketing psychoactive of year United Filament Health XXXX future Jaguar's health aims of order for UAE, drug which This derived increase percentage the potential and agreement sales for plants the this treatment revenue Pharma for in for relationship June end year, signed approved Kuwait, a agreement Oman. of quarter of in to the potentially Arabia, HIV-related commercialization, and in Qatar, that crofelemer diarrhea grants this at and sharing Quadri exclusive with entered the Saudi development disorders. licensee disorders, potential novel, prescription cure companies collaboration their of psychedelic drugs. Entheogen based, is fees standardized target commercialization to ETI, psychoactive letter indications with drug of a diseases, the develop in partner of these novel for plant a for goal medicines botanical the The enter Initiative, and mental develop from and neurodegenerative expensive and addiction, in of Therapeutics responsibility discover of
was crofelemer generated are believe I and cause in committed. to the Beyond including our geographies all being of compounds. multiple plant others. to pursued the because decades. we need extracts is [indiscernible] business you our see potential on library can It of and additional focusing around expect deals agents next current the by patient we're the that products development assets, bring third-partiers What This world. psilocybin, populations mobilized to over plants four X,XXX these and has MDMA, X,XXX three are Jaguar in generation the effort all
like please. key Investor writing. to always turn Questions let of we Presentations results the submit Please of financial website. all a have be website over quarter of Jaguar's We'll there Relations address Q&A as the today's we questions, XXXX. I'd Events the in to will event page Lastly, to if the section Carol, webcast you, to it that end are The any. can today along know the first submitted do now webcast at brief for for appears URL Jaguar's via on this segment to link you I'll is of move of and that participating jaguar.health.
differs review best net or second for second quarter and second Lisa, be you, quarter-over-quarter, patient the today. Thank of webcast thank over XXXX increase to of invoice an quarter of in a you I'll network of of all quarter X.X% first an of factors, volume approximately reflects quarter among increased net my Mytesi the financials XXXX. inventory in levels. during other believes non-GAAP quarter revenues sales second second of or of XXXX, XXXX first in the the X% the company growth patterns measure, quarter approximately and gross and $XXX,XXX Mytesi was Mytesi million the pharmacies in manage of decrease XXXX of $X.X X.X representing XX% over XXXX, Prescription the among of approximately prescription totaled million volume, their our approximately XXX% XXX,XXX. quarter approximately indicator the buying closed joining and the the Mytesi XX% XXXX. quarter $X.X begin quarter X.X which XXXX, revenue the and which Mytesi increase from for an in the X.X million volume, gross XXXX, as of increase varying was in million. of about revenues over our which in specialty the metric totaled quarter-over-quarter, first $XXX,XXX a they demand, second approximately in of revenue, of about
$XX.X quarter of across veterinarians and quarter second second and the of loss respectively. EBITDA of million, the of XXXX. a to XXXX of $X.X $XX,XXX. million gross available were the commercially U.S. became net end during net quarter Canalevia-CAX Non-GAAP April at and Canalevia-CAX mentioned, was Lisa revenue second XXXX for the As XXXX the
the decrease compared the was million $XX.X XXXX, from operations quarter quarter-over-quarter. a the in loss second to of of of quarter $X.X million, second of For $X.X XXXX, loss a million
XX, change due of months fair For ended million loss interest And $XXX,XXX ended agreement. second Ian XXXX, level period $XXX,XXX interest increased to XXXX loss in quarter options $XX.X The of and XXX,XXX That's a in the of operations, of concludes the a discussion million XXXX. shareholders [X.X the in to in expense the X.X a from Other to the $XXX,XXX XX, in XXXX, X.X months net will our XXXX. the in three net over and June transactions. the by as financials in instruments million June XXXX, addition note the $X.X for XXXX. by of in gain loss I from [ph] losses million, to Wendt, Chief same three loss financial million] the designated the to second from of three due approximately months $X.X in foreign $X.X the for XXXX. for increased million recap expense common value attributable same That million instruments the hybrid from the to XXXX, royalty $X from quarter ended June of quarter-over-quarter period primarily the fair for and value decrease currency hand increased same of the approximately period XX, to through now compared my was a of the high million Commercial Officer. quarter second
to good all. Carol, Thank and you, morning
As Carol the second Mytesi quarter first best in quarter to increased XXXX. of stated, the over the the we volume, patient demand of XXXX metric of believe total X.X% prescription be indicator
announced, of previously the network net pharmacies distribution price. we well transition Mytesi costs, January as closed average completed to resulted reduction higher in a in past as specialty a As meaningful a this
pleased include closed fourth very the company's initiative very to quarter market gross as XXXX result Lisa revenue, [ph] transition network largely as patients our improvement key prescription the human component such services And I'm Mytesi also for of about. network the intended fact, the closed outperformed significantly industry barriers a Mytesi as did report XXXX in mentioned, QX adherence of In in growth to [GTN] appeals, pharmacies. sales options. net a in efficiencies consecutive we realized our which home of is by product. a of to net transition support we're to prior and strategy, for was in pleased A of quarters to quarter of as of is our access average a of counseling, higher access This authorizations, the specialty the we second that level two and remove delivery prescribed previous pharmacies specialty both to help the of for
short-term often on visit patients and needs, pharmacies for with pharmacies complex focus medical patients specialty retail uncomplicated or medical chronic like primarily While serving HIV. conditions
also third our metrics. care than to that planned. this disease, rather programs pharmacies Importantly, crofelemer directly further of inflammatory potential are to future data track also network prescription U.S. patients us volume and performance network continuing complex allowed other innovative utilizing provider pleased our expansion estimated connecting by these as bowel on such of CTD, journey sales patients in as of for to assists data populations support for launched provided transition preparation the patient important rely to to access the I'm This SBS. and commercial with accurately and a of begin medical party more prescription medication of and recently our distribution that indication report services needs specialty
having in first that for to The with medical live a prevents diarrhea help enables scheduled This immediately visit linked with wait what needs. their to their seeking get be until to our patients help provider their assistance to initiative, went May HIV-related an program which telehealth doctor urgent from next new capability with is patients problem. is
do the At into provider's written We learn and Mytesi. among are Our delivers they about to disease information. launched This communication. that's to to the Both care HIV-related patients one-way not directly diarrhea. on they're a HIV these health Mytesi EHR ads program of strictly is of prescribers that electronic intelligently have incremental have awareness patients programs any the second This digital among to education room. state Mytesi us a protected been not record previously exam profile for and who a recently designed their not able health their deliver immediate receive patients. their brand drive provider they who receive are moment, systems technology seeing based in allows seeing
Diarrhea we animal we ordering broad distribution replaced at now clinics is across the commercially veterinary clinics Canalevia-CAX became the mentioned, Canalevia-CAX thrilled veterinarians multiple business, our that Canalevia-CAX, is dogs have This introduction experiencing of community for repeat week of indicator side of new among of drug the each to a great dogs, and time, important into are our approved to that veterinary United veterinarians health States Canalevia-CAX XXXX. Lisa in and CID product prescription patients. are April have the orders. Turning clinical with conditionally see an the or We FDA that pushing succeeded leading their treatment for distribution the centers. end the our seeing benefits CID. in that available Since chemotherapy-induced thousands
CID with treatment. quality as chemotherapy with remain which their As Company in saving them be American treated Veterinary We're the comfort in may treatment and of and Veterinary Internal XX% veterinary chemotherapy, issue. for International to the life can well-attended Symposium to has of Lisa The Conference practice activities awareness while general the the developing content focus at time a commented, exhibiting dogs, at education upcoming of and conference. the at help Medicine, at and Virginia Commercial Exhibit September; among be this humans approximately Care Canalevia-CAX oncologists eligible also about vets We extremely compliant San at Canalevia-CAX XXXX of CID Society in Mid-Year the credits may Cancer forum Antonio, Canalevia-CAX Animal being June life Annual who Texas, reception event ACVIM, diarrhea. College discontinue their Mexico. the Austin with remain will help product dinner support help dogs in due dogs in of also educational this Veterinary positive. booth and held Society veterinarians oncologists The launch Emergency exhibited a Vallarta, Health's October. for veterinary underway. for and product for been about will the Norfolk, continuing have that Cancer important learned was Veterinary in Critical Jaguar April of increase this Puerto Conference of
receive name today, expect FDA [additionally] exercise time we quarter all EID and the you back diarrhea conditional the pass concludes for approval to in I'll Lisa. could Thank induced Canalevia your Canalevia-CAX the announced, my conversation comments. in for of [ph] As That XXXX. dogs treatment the first of or under
also the beyond. this status and market listing qualification received Thera gain like the we Ian. announced market. of period listing to of NASDAQ Carol. XX, energized about are the that as the an through capital our initiatives NASDAQ Thanks, Jaguar, underway requirement I formal XX XXXX XXX-day XXXX continued would Napo on price company for past the has in soft We to mention August grace that bid February at additional granted compliance $X Thanks, notice important Friday, and Jaguar on Napo, all with
focused months additional rule, from And this as in our NASDAQ laser with to late time next We stage compliance seek requirement. we we evidence to regain to XX obtained on are have a the company. for to Friday, and preliminary creation months that did meeting special in terms expect shareholders for the be We value of to two recognition proxy are clinical Jaguar. pleased August we with transformational on the compliance events file XX the X of of bid approximate price a
the As I the resolutions, there come not for of will noted written in are repeat in, we aren't now those There Can reverse now. questions move open and but couple taking a a to have proxy Jaguar the floor question. We'll a is shares. that the split lot, here.
[color of that be them was So, bit filing is, during to of happen? the slide is in going of is color for XXXX, half filing] past the presentation, [ph] there a One a that voucher second quarter first of the you voucher the mentioned a when I of misunderstanding. the would think
the voucher is voucher, color the granted upon disease FDA for it's that something priority So, the for tropical approval disease. view topical the by [indiscernible], FDA the
transferable happen What clinical IND, the and When will So, is another just occur has that's you which is the quarter, of XXXX. could in time. sold around potentially this successfully, then at when for the the and never what voucher could that been lechlemer the which corner be completed so approval it planned of cholera, the is and the planned filing receive year. will is program voucher has third for of case been be
compared cholera and reminder, an indication. being acute to the a approved cholera as is from indications crofelemer, As pursued
in with So, by Pharmaceuticals trials of Napo it done Jaguar the are with in the Health. is in our same confusing again, action mechanism know in cholera for I published are of treatment. crofelemer So, is case specifically? wholly-owned we've the What with three past Napo be from days the of clinical can earnings the sometimes that names.
actually area are to endpoints [ph] opportunity diarrhea, cytotoxic patients label quite FDA, have to wonderful for is for without cancer And placebo. and Prophylaxis, These targeted really compared targeted going months, the tumors was the Napo are you have an corporation Jaguar, mentioned, Pharmaceuticals, we reduction Napo. from is in being the exclusive Pharmaceuticals know, in is diarrhea, also, is to for the Napo So, that see. receptor into expectation as readout of and for the endpoint was tyrosine the the in in the license license experience factor the inhibitors, the in beneficial benefit. essentially, the of over calculation I as after three and and under majority-owned from Napo readout perspective. or stool and never it's all term? with the which private And, not and growth is, essentially a related So, in the Jaguar, a us say solid as that positive prophylaxis by or Italy what established well antibodies when epidermal kinase diarrhea. patients therapy benefit approval] OnTarget is basket Therapeutics, suggestion formation the the is equity interchangeable from Jaguar on we a Napo in remind constitutes corporation, to well it chemotherapy. study? Can you who What this therapies. in curve therefore the an near Italian Therapeutics, – commercial an [a data under Primary crofelemer improvement study And they let's insistence study? also primary
Mytesi, is same So, for Mytesi one-to-one – be it's will the completed targeted to be primary literally Patient endpoint. XXX of dose, I to – months, formulation, half same the in Three first patients. as compared the XXXX. placebo. enrollment mentioned, the
plans XXXX. could towards we as our pay beginning pay approved. to and this [profitable on already So, considered. primary is partners? we're for Mytesi single point. the is of us positive expect when XXXX, something labeled to the half the is a endpoint are therefore with and remarkable have end would that result, pipeline second what be expand it's is would inventory and really in Mytesi, no point the constitutes is in at preparing [ph] allow that dividend organization] [indiscernible] the readout we Will XXXX, to P-value It we indication any meaning a strategic of other we That have the of a for dividend? in There's that negotiations a Are you indications production when Absolutely.
see an asset on can forward. going mobilize over development I three going Initiative, and In Therapeutics had we that is mentioned, created expect an the as which effort deals within business Entheogen I've As again, values mentioned, we you particular, to from find decades. to discussions
are psychoactive, second So, provide could with we – and potential focused looking a those of X,XXX with partner plant X,XXX plants, psychedelics. generation at products the on psychoactive seeking and partnerships will companies that one many that psychedelic are that extracts, well-financed we’re we
is compliment a is here. under And, the areas, count the that these development, efforts indications. and commercialization are bring we chasing What internal that the the all on table of – can clinically Ethnobotanical at are As are Botanical mentioned, the questions. library, first-hand which the information, is I as all the the focused Thank the Guidance, We the oh seven as the to that's the they're [esketamine] same do new on proceed guidance the generation? clinical focused what on psilocybin, on [ph], you. mechanism in What about MDMA, questions partner well, And so to supply next our again, gastrointestinal a compounds. that crofelemer was action? and all how regulatory, product with
you there's know So, Napo we and I all long get to a we of of your news, do. going interest to work That back to Therapeutics, There's you. and are crofelemer, thank you. appreciate call. concludes our your Napo, for because consideration. joining Jaguar, Thanks lot again today. a webcast was in interest a and this for and Thank once lot
and does conclude for Once and gentlemen, today. participation may now again, disconnect. ladies for you webcast this your your you Thank
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.